FrancophonIA/ELRC3.0 huggingface dataset:
English: Based on a recommendation by an external Data Monitoring Committee, the accrual in the pembrolizumab monotherapy arm was stopped for patients whose tumours express PD-L1 with a CPS < 10.
Danish: På basis af en anbefaling fra en ekstern datamonitoreringskomité blev tilgangen af patienter i armen med pembrolizumab som monoterapi stoppet for patienter, hvis tumorer udtrykker PD-L1 med CPS < 10.
English: Disease characteristics were squamous (18%) and non-squamous (82%); M1 (99%); and brain metastases (9%).
Danish: Sygdomskarakteristika var planocellulær (18%) og ikke-planocellulær (82%), M1-stadie (99%) og hjernemetastaser (9%).
English: Immune-related adverse reactions (see section 4.4)
Danish: Immunrelaterede bivirkninger (se pkt.
English: The recommended dose of KEYTRUDA as part of combination therapy is 200 mg every 3 weeks administered as an intravenous infusion over 30 minutes.
Danish: Den anbefalede dosis af KEYTRUDA som en del af kombinationsbehandling er 200 mg hver 3. uge administreret som intravenøs infusion over 30 minutter.
English: It is available in cartons containing one glass vial.
Danish: Det fås i pakninger med et hætteglas.
English: Table 20: OS by PD-L1 Expression
Danish: Tabel 20: OS ved PD-L1-ekspression
English: Kaplan Meier curves for OS based on the final analysis are shown in Figures 13 and 14.
Danish: Kaplan Meier-kurver for OS baseret på den endelige analyse er vist i figur 13 og 14.
English: Seventy-four percent of patients had received Auto-SCT, 26% were transplant ineligible, and 45% of patients had prior radiation therapy.
Danish: 74% af patienterne havde gennemgået ASCT, 26% var uegnede til transplantation, og 45% af patienterne havde tidligere fået strålebehandling.
English: An HR=0.96 [95% CI 0.37,2.52] in OS, an HR=0.60 [95% CI 0.29,1.21] in PFS, and an ORR of 47% and 42% for pembrolizumab combination vs chemotherapy was reported within this study subgroup.
Danish: En HR=0,96 [95% CI 0,37; 2,52] for OS, en HR=0,60 [95% CI 0,29; 1,21] for PFS, og en ORR på 47% og 42% for kombinationsbehandlingen med pembrolizumab versus kemoterapi blev rapporteret i denne studiesubgruppe.
English: A subgroup analysis was performed as part of the final analysis of KEYNOTE-002 in patients who were PD-L1 positive (PD-L1 expression in ≥ 1% of tumour and tumour-associated immune cells relative to all viable tumour cells - MEL score) vs. PD-L1 negative.
Danish: Der blev udført en subgruppeanalyse som en del af den endelige analyse i KEYNOTE-002 hos patienter, der var PD-L1-positive (PD-L1-ekspression i ≥ 1% af tumorcellerne og tumor-associerede immunceller i forhold til alle levedygtige tumorceller - MEL-score) versus PD-L1-negative.
English: What KEYTRUDA contains The active substance is pembrolizumab.
Danish: Keytruda indeholder: - Aktivt stof: pembrolizumab.
English: Patients were randomly assigned to receive pembrolizumab at a dose of 2 mg/kg every 3 weeks or 10 mg/kg every 3 weeks.
Danish: Patienterne blev randomiseret til at få enten pembrolizumab i en dosis på 2 mg/kg hver 3. uge eller 10 mg/kg hver 3. uge.
English: Among 370 patients with urothelial carcinoma who were not eligible for cisplatin-containing chemotherapy baseline characteristics were: median age 74 years (82% age 65 or older); 77% male; and 89% White and 7% Asian.
Danish: Blandt de 370 patienter med urotelialt karcinom, som var uegnede til cisplatinbaseret kemoterapi var baseline-karakteristika følgende: median alder 74 år (82% i alderen 65 år eller ældre); 77% mænd; og 89% hvide og 7% asiater.
English: The median trough concentrations (Cmin) at steady-state were approximately 22 mcg/mL at a dose of 2 mg/kg every 3 weeks and 29 mcg/mL at a dose of 200 mg every 3 weeks.
Danish: Den mediane dalkoncentration (Cmin) ved steady state var ca. 22 μg/ml ved en dosis på 2 mg/kg hver 3. uge og 29 μg/ml ved en dosis på 200 mg hver 3. uge.
English: This 96 hour hold may include up to 6 hours at room temperature (at or below 25°C).
Danish: Disse 96 timer kan inkludere opbevaring i op til 6 timer ved stuetemperatur (ved eller under 25 °C).
English: Pembrolizumab may be restarted within 12 weeks after last dose of KEYTRUDA if the adverse reaction remains at Grade ≤ 1 and corticosteroid dose has been reduced to ≤ 10 mg prednisone or equivalent per day.
Danish: Behandlingen med pembrolizumab kan genoptages inden for 12 uger efter den sidste dosis af KEYTRUDA, hvis bivirkningen forbliver ≤ grad 1, og kortikosteroiddosis er blevet reduceret til ≤ 10 mg prednison dagligt eller ækvivalent hermed.
English: A subgroup analysis was performed as part of the final analysis of KEYNOTE-006 in patients who were PD-L1 positive (n=671; 80%) vs. PD-L1 negative (n=150; 18%).
Danish: Der blev udført en subgruppeanalyse som en del af den endelige analyse i KEYNOTE-006 hos patienter, der var PD-L1-positive (n=671; 80%) versus PD-L1-negative (n=150; 18%).
English: Rare toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema nodosum hair colour changes, lichenoid keratosis, papule
Danish: Sjælden toksisk epidermal nekrolyse, StevensJohnsons syndrom, erythema nodosum ændret hårfarve, likenoid keratose, papel
English: KEYTRUDA, in combination with axitinib, is indicated for the first-line treatment of advanced renal cell carcinoma (RCC) in adults (see section 5.1).
Danish: KEYTRUDA, i kombination med axitinib, er indiceret til førstelinjebehandling af fremskredent renalcellekarcinom (RCC) hos voksne (se pkt.
English: Based on the severity of the adverse reaction, pembrolizumab should be withheld or permanently discontinued, and corticosteroids should be administered (see section 4.2).
Danish: På basis af bivirkningens sværhedsgrad skal pembrolizumab pauseres eller seponeres permanent, og kortikosteroider skal administreres (se pkt.
English: Patients on chemotherapy who experienced independently-verified progression of disease were able to crossover and receive pembrolizumab.
Danish: Patienter i behandling med kemoterapi, som oplevede uafhængigt verificeret sygdomsprogression, kunne krydse over til pembrolizumab.
English: A total of 57 NSCLC patients aged ≥ 75 years were enrolled in study KEYNOTE-189 (35 in the pembrolizumab combination and 22 in the control).
Danish: I alt 57 NSCLC-patienter ≥ 75 år var inkluderet i KEYNOTE-189-studiet (35 i kombinationsbehandlingen med pembrolizumab og 22 i kontrolgruppen).
English: Efficacy results were similar for the 2 mg/kg and 10 mg/kg pembrolizumab arms.
Danish: Effektresultaterne var sammenlignelige i armene med 2 mg/kg og 10 mg/kg pembrolizumab.
English: Each vial contains an excess fill of 10 mg (0.4 mL) to ensure the recovery of 50 mg of KEYTRUDA per vial.
Danish: Hvert hætteglas indeholder et overskud på 10 mg (0,4 ml) for at sikre, at der kan udtrækkes 50 mg KEYTRUDA pr. hætteglas.
English: Data from pembrolizumab monotherapy in patients with resected Stage III melanoma, from pembrolizumab in combination with axitinib in patients with advanced RCC, from chemotherapy combination in patients with metastatic NSCLC, and from pembrolizumab (with or without chemotherapy) in patients receiving first-line treatment for metastatic or unresectable recurrent HNSCC ≥ 75 years are limited (see sections 4.4 and
Danish: Data fra pembrolizumab som monoterapi hos patienter med resekteret stadie III-melanom, fra pembrolizumab i kombination med axitinib hos patienter med fremskredent RCC, fra kombinationsbehandling med kemoterapi hos patienter med metastatisk NSCLC, og fra pembrolizumab (med eller uden kemoterapi) hos patienter i førstelinjebehandling for metastatisk eller inoperabelt recidiverende HNSCC ≥ 75 år er begrænsede (se pkt.
English: Continuation of pembrolizumab may be considered, after corticosteroid taper, if needed (see section 4.2).
Danish: Det kan overvejes at fortsætte behandlingen med pembrolizumab efter langsom udtrapning af kortikosterioder, hvis det er nødvendigt (se pkt.
English: The safety of pembrolizumab was evaluated in a 1-month and a 6-month repeat-dose toxicity study in Cynomolgus monkeys administered intravenous doses of 6, 40 or 200 mg/kg once a week in the 1-month study and once every two weeks in the 6-month study, followed by a 4-month treatment-free period.
Danish: Pembrolizumabs sikkerhed blev vurderet i toksicitetsstudier med gentagne doser af 1 måned og 6 måneders varighed, hvor cynomolgusaber fik administreret intravenøse doser på 6, 40 eller 200 mg/kg en gang om ugen i studiet af 1 måneds varighed og en gang hver anden uge i studiet af 6 måneders varighed, efterfulgt af en behandlingsfri periode på 4 måneder.
English: If you have any questions about these medicines, ask your doctor.
Danish: Spørg lægen, hvis du har eventuelle spørgsmål vedrørende disse lægemidler.
English: Use of pembrolizumab in urothelial cancer for patients who are considered ineligible for cisplatincontaining chemotherapy and whose tumours express PD-L1 with CPS ≥ 10
Danish: Brug af pembrolizumab ved urotelial cancer til patienter, som er uegnede til behandling med cisplatinbaseret kemoterapi, og hvis tumorer udtrykker PD-L1 med CPS ≥ 10
English: KEYNOTE-361 is an ongoing Phase III, randomised, controlled, open-label clinical trial of pembrolizumab with or without platinum-based combination chemotherapy versus chemotherapy as first-line treatment in subjects with advanced or metastatic urothelial carcinoma.
Danish: KEYNOTE-361 er et igangværende randomiseret, kontrolleret, åbent klinisk fase III-studie af pembrolizumab med eller uden platinbaseret kombineret kemoterapi versus kemoterapi som førstelinjebehandling hos forsøgspersoner med fremskredent eller metastatisk urotelialt karcinom.
English: Median (95% CI), months
Danish: Median (95% CI), måneder
English: Pembrolizumab concentrations with weight-based dosing at 2 mg/kg every 3 weeks in paediatric patients (2 to 17 years) are comparable to those of adults at the same dose.
Danish: Ved vægtbaseret dosering på 2 mg/kg hver 3. uge hos pædiatriske patienter (2 til 17 år) er koncentrationen af pembrolizumab sammenlignelig med koncentrationen hos voksne ved samme dosis.
English: No dose adjustment is needed for patients with mild or moderate renal impairment.
Danish: Dosisjustering er ikke nødvendig hos patienter med let eller moderat nedsat nyrefunktion.
English: A direct comparison of pembrolizumab when used in combination with chemotherapy to pembrolizumab monotherapy is not available.
Danish: Der foreligger ikke en direkte sammenligning af pembrolizumab ved anvendelse i kombination med kemoterapi i forhold til pembrolizumab som monoterapi.
English: An analysis was performed in KEYNOTE-052 in patients who had tumours that expressed PD-L1 with a CPS < 10 (n=251; 68%) or ≥ 10 (n=110; 30%) based on the PD-L1 IHC 22C3 pharmDx
Danish: Der blev udført en analyse i KEYNOTE-052 hos patienter, som havde tumorer, der udtrykte PD-L1 med CPS < 10 (n=251; 68%) eller ≥ 10 (n=110; 30%) baseret på PD-L1 IHC 22C3 pharmDx
English: Endocrine disorders Very common hypothyroidism hyperthyroidism, hypothyroidism
Danish: Det endokrine system Meget almindelig hypotyroidisme hypertyroidisme, hypotyroidisme
English: In this patient population, the most frequent adverse reactions were anaemia (50%), nausea (50%), fatigue (37%), constipation (35%), diarrhoea (30%), neutropaenia (30%), decreased appetite (28%) and vomiting (25%).
Danish: I denne patientpopulation var de hyppigste bivirkninger: anæmi (50%), kvalme (50%), træthed (37%), obstipation (35%), diarré (30%), neutropeni (30%), appetitløshed (28%) og opkastning (25%).
English: If refrigerated, the vials and/or intravenous bags must be allowed to come to room temperature prior to use.
Danish: Hætteglassene og/eller de intravenøse infusionsposer skal opnå stuetemperatur inden brug, hvis de har været opbevaret i køleskab.
English: Table 15 summarises key efficacy measures.
Danish: I tabel 15 opsummeres de vigtigste effektresultater.
English: , influenza like illness, chills
Danish: , influenzalignende sygdom, kuldegysninger
English: Table 11 summarises efficacy results by PD-L1 expression and BRAF mutation status.
Danish: I tabel 11 opsummeres effektresultater ud fra PD-L1-ekspression og BRAFmutationsstatus.
English: Of the 89 patients receiving 2 mg/kg of pembrolizumab who were previously treated with ipilimumab, 53% were male, 33% were ≥ 65 years of age and the median age was 59 years (range 18-88).
Danish: Af de 89 patienter, som fik 2 mg/kg pembrolizumab, og som tidligere havde været behandlet med ipilimumab, var 53% mænd, 33% var ≥ 65 år, og medianalderen var 59 år (interval: 18-88).
English: *Based on the stratified Cox proportional hazard model
Danish: *Baseret på den stratificerede Cox proportional hazard-model
English: 6-month PFS rate 9-month PFS rate 12-month PFS rate OS
Danish: 6-måneders PFS-rate 9-måneders PFS-rate 12-måneders PFS-rate OS
English: Clear to slightly opalescent, colourless to slightly yellow solution, pH 5.2 - 5.8.
Danish: Klar til let opaliserende, farveløs til lysegul opløsning med pH 5,2-5,8.
English: Seventy percent had at least two and 35% of patients had three or more prior systemic therapies for advanced melanoma.
Danish: 70% af patienterne havde forudgående fået mindst to, og 35% af patienterne havde fået tre eller flere systemiske behandlingsregimer for fremskredent melanom.
English: The effect of hepatic impairment on the clearance of pembrolizumab was evaluated by population pharmacokinetic analyses in patients with mild hepatic impairment (as defined using the US National Cancer Institute criteria of hepatic dysfunction) compared to patients with normal hepatic function.
Danish: Effekten af nedsat leverfunktion på pembrolizumabs clearance blev vurderet ud fra farmakokinetiske populationsanalyser, hvor patienter med let nedsat leverfunktion (defineret i henhold til US National Cancer Institute (NCI) kriterier for leverinsufficiens) blev sammenlignet med patienter med normal leverfunktion.
English: The Kaplan-Meier curve based on the final analysis for OS is shown in Figure 12.
Danish: Kaplan-Meierkurven baseret på den endelige analyse for OS er vist i figur 12.
English: * BICR using RECIST 1.1
Danish: * BICR i henhold til RECIST 1.1
English: Consider the benefit of treatment with pembrolizumab versus the risk of possible GVHD in patients with a history of allogeneic HSCT.
Danish: Fordelene ved behandling med pembrolizumab skal afvejes mod risikoen for mulig GVHD hos patienter, der tidligere har gennemgået allogen HSCT.
English: Number at Risk Pembrolizumab 2 mg/kg: Pembrolizumab 10 mg/kg: Docetaxel:
Danish: Antal i risikogruppe Pembrolizumab 2 mg/kg: Pembrolizumab 10 mg/kg: Docetaxel:
English: Physicians should consider the benefit/risk balance of the available treatment options (pembrolizumab monotherapy or pembrolizumab in combination with chemotherapy) before initiating treatment in previously untreated patients with non-small cell lung cancer whose tumours express PD-L1.
Danish: Lægen bør overveje benefit/risk-forholdet for de tilgængelige behandlingsmuligheder (pembrolizumab som monoterapi eller pembrolizumab i kombination med kemoterapi), før behandling initieres hos tidligere ubehandlede patienter med ikke-småcellet lungecancer, hvis tumorer udtrykker PD-L1.
English: Pembrolizumab must be permanently discontinued for any Grade 3 immune-related adverse reaction that recurs and for any Grade 4 immune-related adverse reaction toxicity, except for endocrinopathies that are controlled with replacement hormones (see sections 4.2 and 4.8).
Danish: Pembrolizumab skal seponeres permanent ved en hvilken som helst immunrelateret bivirkning af grad 3, som recidiverer, og ved alle immunrelaterede bivirkninger af toksicitetsgrad 4, bortset fra endokrinopatier, som kontrolleres med hormonsubstitutionsbehandling (se pkt.
English: Grade ≥ 3 with creatinine > 3 times ULN
Danish: Grad ≥ 3 med kreatinin > 3 gange ULN Seponer behandlingen permanent
English: Patients were randomised (1:1) to receive pembrolizumab at a dose of 200 mg every 3 weeks (n=154) or investigator's choice platinum-containing chemotherapy (n=151; including pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabine+cisplatin, gemcitabine+carboplatin, or paclitaxel+carboplatin.
Danish: Patienterne blev randomiseret i forholdet 1:1 til pembrolizumab i en dosis på 200 mg hver 3. uge (n=154) eller investigators valg af platinbaseret kemoterapi (inklusive pemetrexed+carboplatin, pemetrexed+cisplatin, gemcitabin+cisplatin, gemcitabin+carboplatin eller paclitaxel+carboplatin; n=151.
English: A HR=2.09 [95% CI 0.84,5.23] in OS and HR=1.73 [95% CI 0.77,3.90] in PFS for pembrolizumab combination vs chemotherapy was reported within this study subgroup.
Danish: En HR = 2,09 [95% CI 0,84; 5,23] for OS og HR = 1,73 [95% CI 0,77; 3,90] for PFS for kombinationsbehandlingen med pembrolizumab versus kemoterapi blev rapporteret i denne studiesubgruppe.
English: Pneumonitis resolved in 138 patients, 2 with sequelae.
Danish: Pneumonitis gik over hos 138 patienter, 2 med sequelae.
English: Discard any unused portion left in the vial.
Danish: Den ubrugte rest i hætteglasset bortskaffes.
English: Adrenal insufficiency (primary and secondary) has been reported in patients receiving pembrolizumab.
Danish: Binyrebarkinsufficiens (primær og sekundær) er rapporteret hos patienter, der fik pembrolizumab.
English: Eighty-six percent had a primary tumour in the lower tract and 14% had a primary tumour in the upper tract.
Danish: 86% havde en primær tumor i de nedre urinveje, og 14% havde en primær tumor i de øvre urinveje.
English: How you are given KEYTRUDA
Danish: Sådan får du Keytruda
English: Best Overall Response* by IRO ORR %, (95% CI) Complete response Partial response Disease Control Rate % Response Duration Median in months (range) % ongoing at 24 months PFS Median in months (95% CI) PFS rate at 12 months OS Median in months (95% CI)
Danish: Bedste samlede respons* bedømt ved IRO ORR %, (95% CI) Komplet respons Partielt respons Sygdomskontrolrate % Responsvarighed Median i måneder (interval) % igangværende i måned 24 PFS Median i måneder (95% CI) PFS-rate i måned 12 OS Median i måneder (95% CI)
English: The safety of pembrolizumab as monotherapy has been evaluated in 154 paediatric patients with advanced melanoma, lymphoma, or PD-L1 positive advanced, relapsed, or refractory solid tumours at 2 mg/kg every 3 weeks in the Phase I/II study KEYNOTE-051.
Danish: Pembrolizumabs sikkerhed som monoterapi blev vurderet hos 154 pædiatriske patienter med fremskredent melanom, lymfom eller PD-L1-positive fremskredne, recidiverende eller refraktære solide tumorer ved en dosis på 2 mg/kg hver 3. uge i fase I/II-studiet KEYNOTE-051.
English: The following side effects have been reported in clinical trials with pembrolizumab in combination with axitinib:
Danish: Følgende bivirkninger er indberettet i kliniske studier med pembrolizumab i kombination med axitinib:
English: • Do not co-administer other medicinal products through the same infusion line.
Danish: • Keytruda må ikke administreres sammen med andre lægemidler i samme infusionsslange.
English: There is limited data on subjects with stage IIIA according to AJCC 8
Danish: Der er begrænsede data vedrørende forsøgspersoner med stadie IIIA i henhold til AJCC, 8. udgave, på tidspunktet for RFS-analysen.
English: Pembrolizumab has not been studied in patients with severe renal impairment.
Danish: Pembrolizumab er ikke undersøgt hos patienter med svært nedsat nyrefunktion.
English: The 18-month OS rate was 81.0% (95% CI 76.7, 84.6) for pembrolizumab in combination with axitinib and 70.7% (95% CI 65.8, 75.1) for sunitinib.
Danish: OS-raten i måned 18 var 81,0% (95% CI: 76,7; 84,6) for pembrolizumab i kombination med axitinib og 70,7% (95% CI: 65,8; 75,1) for sunitinib.
English: All but one patient was white.
Danish: Alle på nær en patient var kaukasere.
English: For subjects with relapsed or refractory classical Hodgkin lymphoma, clinical data for the use of pembrolizumab in patients ineligible to ASCT due to reasons other than failure to salvage chemotherapy are limited (see section 5.1).
Danish: For så vidt angår recidiverende eller refraktært klassisk Hodgkins lymfom foreligger der kun begrænsede kliniske data for anvendelse af pembrolizumab hos patienter, som er uegnede til ASCT af andre årsager end behandlingssvigt efter salvage-kemoterapi (se pkt.
English: Patients were randomised (1:1:1) to receive pembrolizumab at a dose of 2 (n=344) or 10 mg/kg (n=346) every 3 weeks or docetaxel at a dose of 75 mg/m2 every 3 weeks (n=343) until disease progression or unacceptable toxicity.
Danish: Patienterne blev randomiseret i forholdet 1:1:1 til at få pembrolizumab i en dosis på 2 mg/kg (n=344) eller 10 mg/kg (n=346) hver 3. uge eller docetaxel i en dosis på 75 mg/m2 hver 3. uge (n=343) indtil sygdomsprogression eller uacceptabel toksicitet.
English: Boehringer Ingelheim (BIB) Pharma GmbH & Co. KG Birkendorfer Straße 65 88397 Biberach an der Riss Germany
Danish: KG Birkendorfer Straße 65 88397 Biberach an der Riss Tyskland
English: The pembrolizumab monotherapy arm remains open only to patients whose tumours express PD-L1 with a CPS ≥ 10.
Danish: Armen med pembrolizumab som monoterapi forbliver kun åben for patienter, hvis tumorer udtrykker PD-L1 med CPS ≥ 10.
English: The efficacy of pembrolizumab in combination with pemetrexed and platinum chemotherapy was investigated in a multicentre, randomised, active-controlled, double-blind trial, KEYNOTE-189.
Danish: Pembrolizumabs virkning i kombination med pemetrexed og platinbaseret kemoterapi blev undersøgt i et randomiseret, aktivt kontrolleret, dobbeltblindet multicenterstudie, KEYNOTE-189.
English: Response was assessed in KN087 and KN013 every 12 and 8 weeks, respectively, with the first planned post-baseline assessment at week 12.
Danish: (KEYNOTE-087) / 8. uge (KEYNOTE-013) med den første planlagte vurdering efter baseline i uge 12.
English: Number at Risk Pembrolizumab + Axitinib:
Danish: Antal i risikogruppe Pembrolizumab + Axitinib:
English: Confirmed ORR
Danish: Middel risiko Høj risiko Bekræftet ORR
English: The following side effects have been reported with pembrolizumab alone:
Danish: Følgende bivirkninger er indberettet med pembrolizumab alene:
English: In this patient population, the most frequent adverse reactions were diarrhoea (54%), hypertension (45%), fatigue (38%), hypothyroidism (35%), decreased appetite (30%), palmar-plantar erythrodysaesthesia syndrome (28%), nausea (28%), ALT increased (27%), AST increased (26%), dysphonia (25%), cough (21%), and constipation (21%).
Danish: I denne patientpopulation var de hyppigste bivirkninger: diarré (54%), hypertension (45%), træthed (38%), hypotyroidisme (35%), appetitløshed (30%), palmoplantar erytrodysæstesisyndrom (hånd-fod-syndrom) (28%), kvalme (28%), forhøjet ALAT (27%), forhøjet ASAT (26%), dysfoni (25%), hoste (21%) og obstipation (21%).
English: Pembrolizumab doses of 2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks, and 10 mg/kg every 2 weeks were evaluated in melanoma or previously treated NSCLC clinical trials.
Danish: Pembrolizumab-doser på 2 mg/kg hver 3. uge, 10 mg/kg hver 3. uge og 10 mg/kg hver 2. uge blev vurderet i kliniske studier af melanom-patienter eller NSCLC-patienter, som tidligere har været behandlet.
English: Renal cell carcinoma KEYNOTE-426: Controlled trial of combination therapy in RCC patients naïve to treatment The efficacy of pembrolizumab in combination with axitinib was investigated in KEYNOTE-426, a randomised, multicentre, open-label, active-controlled trial conducted in patients with advanced RCC with clear cell component, regardless of PD-L1 tumour expression status and International Metastatic RCC Database Consortium (IMDC) risk group categories.
Danish: KEYNOTE-426: Kontrolleret studie af kombinationsbehandling hos behandlingsnaive RCC-patienter Pembrolizumabs virkning i kombination med axitinib blev undersøgt i KEYNOTE-426, et randomiseret, åbent, aktivt kontrolleret multicenterstudie hos patienter med fremskredent RCC med en clear cellkomponent, uanset PD-L1-tumorekspressionsstatus og risikogruppekategorier i henhold til IMDC (International Metastatic RCC Database Consortium).
English: Table 13 summarises key efficacy measures.
Danish: I tabel 13 opsummeres de vigtigste effektresultater.